Trial Profile

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tigilanol tiglate (Primary)
Indications Leiomyosarcoma; Osteosarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Sponsors QBiotics

Most Recent Events

25 Jun 2025 According to a QBiotics media release, primary endpoint (Tumour Response) has been met.
25 Jun 2025 According to a QBiotics media release, Tigilanol tiglate met both its primary and secondary endpoints by the end of stage 1, and the company has moved ahead with stage-2 which is opening shortly at Memorial Sloan Kettering Cancer Center in New York, USA.
25 Jun 2025 Results presented in the QBiotics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com